Tirzepatide Program

Tirzepatide labeling advises switching to a non-oral contraceptive or adding a barrier method for four weeks after initiation and for four weeks after each dose escalation. Discuss this with your clinician before starting.

Semaglutide, tirzepatide, and liraglutide products carry a boxed warning about thyroid C-cell tumors observed in rodents; the relevance to humans is unknown. They are contraindicated with a personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN2), or serious hypersensitivity to the prescribed product.

Risks include nausea, vomiting, diarrhea, constipation, severe gastrointestinal reactions, pancreatitis, gallbladder disease, kidney injury related to dehydration, and serious allergic reactions. Hypoglycemia risk increases with insulin or sulfonylureas. Discuss gastroparesis, diabetic eye disease, pregnancy plans, and all medicines. These products are not recommended with severe gastroparesis. Tell procedural teams about use before anesthesia or deep sedation because pulmonary aspiration has been reported. Seek urgent care for severe persistent abdominal pain, breathing difficulty, or swelling of the face or throat.

FDA approval applies to the specific approved product and its labeling, not to every preparation containing that ingredient. Compounded drugs are not FDA-approved; the FDA does not review them for safety, effectiveness, or quality before marketing. A compounded preparation is not an FDA-approved generic of a brand-name product.